Predictions
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€94.17
28.02.23
28.02.23
€111.20
28.02.24
28.02.24
-13.41%
29.02.24
29.02.24
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€94.17
28.02.23
28.02.23
€117.80
28.02.24
28.02.24
-13.41%
29.02.24
29.02.24
UnitedHealth Group Inc.
Start price
Target price
Perf. (%)
€450.10
28.02.23
28.02.23
€569.31
28.02.24
28.02.24
1.53%
29.02.24
29.02.24
Henry Schein Inc.
Start price
Target price
Perf. (%)
€74.17
28.02.23
28.02.23
€91.27
28.02.24
28.02.24
-4.57%
29.02.24
29.02.24
Intuitive Surgical Inc
Start price
Target price
Perf. (%)
€289.75
29.05.23
29.05.23
-
29.05.24
29.05.24
22.71%
15.02.24
15.02.24
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€40.50
02.02.24
02.02.24
-
-
03.02.24
03.02.24
Could be worthwhile Investment >10% per year
Johnson & Johnson
Start price
Target price
Perf. (%)
€153.36
24.01.23
24.01.23
€160.00
24.01.24
24.01.24
-4.60%
25.01.24
25.01.24
Could be worthwhile Investment >10% per year
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.96
02.01.24
02.01.24
€80.00
02.02.24
02.02.24
-6.29%
22.01.24
22.01.24
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€529.00
18.12.23
18.12.23
€558.00
18.12.24
18.12.24
6.62%
06.01.24
06.01.24
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€68.08
03.01.23
03.01.23
-
03.01.24
03.01.24
-32.29%
28.12.23
28.12.23
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
High dividend yield expected
Good rating
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€526.00
14.12.23
14.12.23
€558.00
14.12.24
14.12.24
0.57%
18.12.23
18.12.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€568.50
11.10.23
11.10.23
€558.00
11.10.24
11.10.24
-7.48%
14.12.23
14.12.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.86
04.11.23
04.11.23
€89.00
04.12.23
04.12.23
-4.82%
05.12.23
05.12.23
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Exact Sciences
Start price
Target price
Perf. (%)
€55.41
11.11.23
11.11.23
€105.00
11.12.23
11.12.23
7.56%
25.11.23
25.11.23
Revenue growth >5% per year expected
Rising EBIT margin expected
Standard Investments for future growth
negative Cash Flow expected
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€370.05
04.11.22
04.11.22
€610.00
04.11.23
04.11.23
44.17%
05.11.23
05.11.23
Top 10 in its market
Could be worthwhile Investment >10% per year
High dividend yield expected
Innovative
Sarepta Therapeutics
Start price
Target price
Perf. (%)
€120.85
29.10.23
29.10.23
€150.00
31.03.26
31.03.26
-
30.10.23
30.10.23
Could be very worthwhile Investment >20% year